Patients with multiple sclerosis have an increased prevalence of sleep disorders compared to the general population, with an estimated rate ranging from 25% to 50% and negative impacts on quality of life.

Vascular dementia accounts for the second most common cause of dementia after Alzheimer’s disease.

Satellos Bioscience Inc. recently presented preclinical data for the novel oral small-molecule AP2-associated protein kinase 1 (AAK1) inhibitor SAT-3247, being developed for the treatment of Duchenne muscular dystrophy and other muscle degenerative diseases, at the Muscular Dystrophy Association conference.

Since microglia play a critical role in resolving amyloid pathology and it has been previously demonstrated that microglia function can be induced by TREM2 activation, TREM2 agonism has been considered a promising novel therapeutic approach to delay or prevent the progression of Alzheimer’s disease.

At the 2024 Alzheimer’s & Parkinson’s Diseases Conference this week, Michel Goedert from the MRC Laboratory of Molecular Biology in Cambridge gave the Donald L. Price Memorial Plenary Lecture entitled, “Cryo-EM structures of disease filaments from human brains.” Donald Price was particularly well-known for his work on plaques and tangles in nonhuman aged primate brains and for the development of several animal models of neurodegenerative diseases.